Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04161911 · ClinicalTrials.gov registry record
A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy
A clinical trial of Hepatocellular Carcinoma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 1,426
- Enrollment target
- 1
- Study location
NCT04161911 is a study of Hepatocellular Carcinoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,426 participants, above the 248-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (475% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04161911, a study of Hepatocellular Carcinoma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 1,426 participants
- Enrollment target
- 1
- Study location
Study Summary
A study to describe real-world treatment patterns and overall survival in advanced liver cancer participants who received second or third line nivolumab therapy
Conditions Studied
Study Locations (1)
New Jersey
- Bristol Myers Squibb, CORDS Research - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,426 participants |
| Start Date | 2018-10-29 |
| Est. Completion | 2018-11-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04161911
The ClinicalTrials.gov registry entry for NCT04161911 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,426 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 248-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (475% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT04161911 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT04161911 about?
NCT04161911 is a clinical study titled "A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy". A study to describe real-world treatment patterns and overall survival in advanced liver cancer participants who received second or third line nivolumab therapy
What is the current status of trial NCT04161911?
This trial is currently completed. The enrollment target is 1,426 participants. The study started on 2018-10-29. Estimated completion is 2018-11-19.
What conditions does trial NCT04161911 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
Who is sponsoring clinical trial NCT04161911?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04161911 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Molecular Basis of Pediatric Liver Cancer
RECRUITING
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.